Since 1858, medicines made by Bristol-Myers Squibb have helped millions of patients around the world fight serious diseases such as cancer, heart disease, diabetes, HIV/AIDS, chronic hepatitis B, rheumatoid arthritis and various psychiatric disorders.
From those early days, we have been developing our offering to better meet the needs of patients. By combining the best elements of a leading-edge biotech company with the resources of a major pharmaceutical company, we are transforming into a new kind of enterprise: a next-generation BioPharma leader.
At the heart of our BioPharma strategy are the medicines that give meaningful hope to patients and physicians and bring value to our shareholders and customers. Since 2002, we’ve introduced eight new products for the treatment of numerous serious diseases.
As well as all these products now on the market, scores of additional investigational medicines are advancing through the company’s pharmaceutical development pipeline. In fact, Bristol-Myers Squibb is recognised as having one of the most productive pipelines in the industry.
Bristol-Myers Squibb News and Awards
We have been listed as one of the best companies to work for by The Sunday Times. We have also been acknowledged as an industry leader in environment, health and safety management.